Springfield, Oregon–(Newsfile Corp. – June 14, 2023) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo” or “the Company”), a pioneer in psilocybin wellness retreats, is excited to announce its feature this Sunday on a groundbreaking CNN documentary episode of The Whole Story with Anderson Cooper.

The episode, entitled ‘Magic Mushrooms: Can They Change Your Mind?’ takes an unprecedented step in mainstream media coverage of psychedelic therapies: CNN Correspondent David Culver undergoes psilocybin therapy on camera, providing viewers with a firsthand perspective on the transformative journey. This is a follow-up on Mr. Culver’s CNN story featuring Silo Wellness last November.

“We’re honored to be part of this monumental moment in mainstream media,” said Oregon attorney Mike Arnold, CEO of Silo Wellness. “This isn’t just a milestone for Silo Wellness, but for the entire field of psychedelic therapy. It’s a significant step towards greater understanding and acceptance.”

Silo Wellness, known for its distinctive retreats in the beautiful landscapes of Jamaica with plans in Oregon, is proud to have facilitated this transformative experience. The episode gives the public an intimate view of participants’ personal healing journeys under the guidance of Silo’s experienced team.

The episode is set to premiere this Sunday, June 18 at 8pm ET/PT. This represents a prime opportunity for potential investors, current shareholders, and the general public to gain an inside look at the innovative work being done at Silo Wellness.

“By showcasing our approach to psilocybin therapy and its profound potential on a platform like CNN, we’re playing a part in normalizing and destigmatizing these treatments, creating value for our shareholders and improving the narrative around mental health care,” added Arnold.

Other Corporate Updates – Debt Settlement

Silo Wellness intends to issue 11,078,959 shares of its common stock to settle the CAD$166,184.38 account payable debt in an arm’s length transaction subject to the statutory four-month hold. The number of shares is determined based on CAD$0.015 per share, the 20-day volume-weighted average price (VWAP) as of Monday, June 12, 2023. Pursuant to CSE Policy 6.2(5) (adopted April 3, 2023), the Company intends to close on the share issuance no sooner than five days. The price protection expires July 22, 2023. In accordance with the previously announced debt restructuring plan, the Company intends to issue shares to settle additional accounts payable and other debt.

Regarding the intended shares for debt announced on April 24, 2023, the Company no longer intends to settle that debt at this time. The parties have agreed to extend the closing of that transaction to contemplate additional opportunities.

For more information about Silo Wellness or to book a Jamaican psychedelic retreat, please visit www.silowellness.com.

Contact:
Mike Arnold, CEO
541-900-5871
IR at silo wellness dot com

About Silo Wellness

Silo Wellness’s mission is to provide psychedelics to those suffering as quickly and inexpensively as possible. Silo is currently Oregon’s only publicly traded company actively providing psychedelics to clients. The Company was founded in 2018 by an Oregon trial lawyer in anticipation of Oregon legalizing psilocybin on January 1, 2023, and currently offers Jamaica psilocybin retreats at an all-inclusive seafront resort. The Company has a right of first refusal on all psilocybin mushrooms with Oregon first-mover cultivator Satya, Inc., and announced in January its intended Portland-area rural psilocybin service center with overnight dorm room accommodations (if land use permits are granted).

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

In this news release, forward-looking statements relate to, among other things, the ability of Silo Wellness to actually increase or maintain revenue and even stay viable as a public company given the capital and revenue deficiencies previously announced. Obtaining profitability and scaling in Jamaica continues to be an uncertain risk along with accomplishing anything licenses in Oregon and then becoming profitable. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements.

Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties, potential impacts of COVID-19, uncertainties regarding the finalization of definitive agreements with the property owner, and the risk of commoditization in the psychedelic market. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness’s continuous disclosure documents available on www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Endexx Year Over Year Annual Revenues Grew 229%

CAVE CREEK, AZ, June 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Endexx® Corporation (OTC: EDXC), a provider of innovative plant-based wellness and nutritional products, today announced the filing of its amended, consolidated, audited fiscal 2022 annual report. Endexx reported the consolidated 10-K audited revenue has grown 229% percent “Year over Year” (YOY) from USD $650,515 for fiscal 2021 to USD $2,138,010 for fiscal 2022, a $1,487,495 or (229%) increase. The amended, consolidated, audited financial statements, including Hyla and CBD Unlimited, report that gross revenue figure. The improvement in gross revenue for fiscal 2022 is attributable to additional revenue realized from the acquisition of Hyla, improved market conditions, new sales channels and improved marketing efforts in promoting the Company’s products. The Company showed a 229% increase in top-line revenue in fiscal 2022, while improving gross profit of $1,193,110 in fiscal 2022 from an equivalent line-item gross loss of $344,078 last year, which represents a positive turn-around of $1,537,188. The YOY in gross profit was attributable to the acquisition of Hyla and to improvements in production costs, and a decrease in inventory impairment between the years.

Endexx 2022 Milestones and Highlights:

• Endexx acquired the controlling interest (51%) of Hyla USA Holdco Limited.
• Endexx grew from 4,000 Mass Retail stores to over 8,000.
• Endexx garnered top 2 selling CBD pain products in Mass Retail Pharmacy in 2022, according to Nielsen Ratings.
• Endexx’s acquisition of HYLA US accelerated its product offerings and revenues in the plant-based, non-nicotine vape and consumable domestic and international markets.

“Consolidating the financials of Hyla into Endexx had an immediate impact on the growth of the Company in Fiscal 2022. This is reflected as a year of expansion and recovery after two years of economic challenges associated with the economy and the pandemic,” stated CEO Todd Davis. Davis added, “Expanding into international markets with Hyla products increased our retail footprint dramatically in Fiscal 2023 Q1 and Q2 and put the Company back into an exponential growth trajectory. We now have delivered to five of the top eight “Mass Retailers” in the US and Hyla has brought us an additional 13 countries with thousands of new distribution points. We anticipate continued growth and challenges in Fiscal 2023 with our Hemp-Derived CBD products and skincare line. However, with the addition of HYLA to our product offerings, we are gearing up for our best year ever in top-line revenues growth and store expansion worldwide.” Mr. Davis continued, “Plant-based, non-nicotine alternatives in the consumer product market have an extremely compelling outlook for Endexx going forward. We believe we have a good possibility that revenues will grow exponentially in this fiscal year continuing into fiscal 2024 and 2025.”

www.endexx.com & www.cbdunlimited.com

www.tryhyla.com

About Endexx Corporation

Endexx Corporation develops and distributes all natural, plant-derived wellness products and topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health. www.endexx.com

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as “estimate,” “commit,” “target,” “goal,” “project,” “plan,” “believe,” “seek,” “strive,” “expect,” “anticipate,” “intend,” “potential” and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements.

Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included “Risk Factors” in our amended Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on June 9, 2023.

For further information, please contact:
Endexx Corporation
Endexx@endexx.com
480-595-6900

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Relationship Set to Accelerate ADHC’s Brands into the $59 Billion CBD Market

Del Mar, California–(Newsfile Corp. – April 5, 2023) – American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce today that the company, through it’s brands UNIVERSAL WELLNESS and Amazon vendor ROLLSCHOICE, has reached a comprehensive alliance with GGII’s leading group of a companies in the CBD and Hemp sector. ADHC’s agreement with Green Globe Intl Group (OTC Pink: GGII), Hempacco (NASDAQ: HPCO) and GGII’s operating subsidiary Green Star Labs provides for a broad range of services and interrelated business activity.

The GGII/HEMPACCO/GREENSTAR group has entered into this alliance with ADHC and will collaborate as outlined below:

1. Formulation, manufacturing, private label, inventory management, packaging and shipment logistics with be provided by Green Star Labs under the Universal Wellness and Rolls Choice Brand.
2. Jointly design a line of CDB, Dietary Supplements and Cosmetic products to be offered through ADHC’ e-commerce platform www.UniversalWellnessShop.com.
3. Introduce and negotiate endorsement agreements with social media influencers and noted HipHop/Rap luminaries. Hempacco currently has relationships deals with Snoop Dogg Brands, rap artist Rick Ross, Hemp Hop Smokables and Cheech and Chong, Hemp Cigarettes.
4. Parties have agreed to a financial partnership including share issuances, line of credit for product inventory, capital formation and addition of future management.
5. Parties have agreed to assess the develop of ADHC existing brand and future products under development, including products sold under the ROLLS CHOICE BRAND of cannabis adhesive pens and UNIVERSAL WELLNESS lifestyle and CBD products.

This alliance is set to springboard ADHC’S branded products into the rapidly growing CDB market sector. A recent report by Market Research Future (MRFR) indicated the CDB market is expected to reach over $59 billion by 2030 an 18% CAGR.
see Cannabidiol (CBD) Market Size Worth USD 59.3 Billion by (globenewswire.com)

“This alliance with ADHC’s Universal Wellness and Rolls Choice brands is great opportunity for us to build revenues with a great partner,” commented Sandro Piancone, CEO of GGII and HPCO. “We look forward to hitting the ground running for a long term mutually beneficial alliance.”

“The GGII/HPCO team is truly brilliant alliance partner for ADHC, we can now focus on pushing our brands to the forefront of the CBD and Cannabis markets with a manufacturing and brand building partner that is a dream come true for our shareholder,” commented ADHC management.

Hempacco

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_001full.jpg

About Hempacco (NASDAQ: HPCO)
Hempacco Co., Inc.’s goal is Disrupting Tobacco’s nearly $1 trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice, and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff functional hemp cigarette and rolling paper brand.

Hempacco’s operating segments include:

1. Manufacturing of smokables, hemp rolling paper, and cannabinoid sticks
2. Smokable technology development
3. The Real Stuff brand of functional smokables and rolling paper
4. Cheech and Chong Hemp Cigarettes and Hemp Hop Smokables with Rick Ross
5. Snoop Dogg Joint Venture of Hemp-Derived Products

Learn more at www.hempacco.com.

Order products at www.realstuffsmokables.com.

About HempBox Vending
HempBox Vending offers a kiosk solution for smart vending technology to sell quickly moving consumer goods, including but not limited to nutraceuticals, CBD, hemp, herb, and spice smokables.

About Green Globe International, Inc. (OTC Pink: GGII)
Green Globe International is a Fast-Moving Consumer Goods incubator and holding company of intellectual property, products, and companies that better people’s lives by helping them feel and look better inside and out.

GGII

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_002full.jpg

Green Globe International (GGII) owns or has interests in several brands and companies including; Green Star Labs, Inc., changing how people feel about themselves inside and out with nutritional supplements, CBD, and beauty products, and hemp CBD cigarette and rolling paper manufacturer Hempacco Co. Inc., (NASDAQ: HPCO) Disrupting Tobacco’s $1 Trillion tobacco industry, with its subsidiaries and joint ventures including HempBox Vending, Inc. a vending and advertising company, Hempacco Paper Company, Inc., producing The Real Stuff Hemp Smokables and hemp paper smoking products like blunts, tubes, and cones, Cali Vibes, Inc. manufacturing cannabinoid cigarettes, HempHop Smokables, Inc., partnering with music producer and rapper Rick Ross, Cheech and Chong Smokables, Inc. delivering cannabinoid Hemp CBD cigarettes to consumers with Cheech and Chong as partners, StickIt USA, Inc., manufacturing a line of cannabinoid sticks, and HPDG, LLC a partnership with Snoop Dogg to develop hemp-derived consumer goods products.

Green Star Labs

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_003full.jpg

Green Globe is publicly traded under the ticker symbol (OTC Pink: GGII). It continues to look for best-in-class companies, products, and patents to create Fast Moving Consumer Goods and channels to sell them, including retail automation and advertising platforms.

Universal Wellness

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_004full.jpg

ABOUT ADHC/UNIVERSAL WELLNESS/ROLLS CHOICE
ADHC is a publicly traded holding company trading under the ticker symbol (OTC Pink: ADHC).
ADHC is currently developing two web-based branded businesses.

1. Universal Wellness
   http://www.UniversalWellnessShop.com (UWS)
   (UWS) is a wellness and lifestyle ecommerce site focused upon providing innovative products, news and the latest health care developments.
2. Rolls Choice is a Southern California based manufacturer, distributer and ecommerce company selling an all-natural Adhesive Glue and application device sold off AMAZON.com and through its own website.

The Pens come in 1 ml, 2 ml and 100 pen packs. Rolls Choice has significant brand awareness in the cannabis industry and boasts over 80,000 followers on Twitter and Instagram. Recently over 12,000 adhesive pens have been manufactured and sold. The adhesive is made of Food Grade Premium ingredients. Rolls Choice Adhesive Pen is Flavorless, Colorless, Tasteless and Stainless. It is used to seal cannabis and tobacco rolled products including blunts, joints, cigars and hand rolled cigarettes in a sterile manner allowing for long lasting adhesive qualities. The proprietary brush tip pen is recommended for precision. RC sells direct to smoke shops, dispensaries and direct to consumers through its e-commerce site. Through the companies multi year history sales over 12,000 adhesive pens and been manufactured and sold by Rolls Choice. see (USPTO ROLLS CHOICE 97278083).

Rolls Choice

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_005full.jpg

ROLLS CHOICE has over 80,000 social media followers which will be introduced to ADHC social media platforms on Twitter, Instagram, Facebook, and TikTok. This relationship will establish a very strong presence providing brand awareness to potential customers and shareholders as the Universal Wellness/Rolls Choice business relationship develops and revenues grow.
Website: www.Rollschoiceadhesive.com
Email: rollschoicerepresentative619@gmail.com
Twitter: https://www.twitter.com/rollschoice
Instagram: https://www.instagram.com/rollschoiceadhesivepen

In addition to the adhesive pen, RC has numerous other cannabis related products being developed that will be introduced as a result of this Acquisition agreement.

Shareholders, customers and other interested parties can find product offerings by searching AMAZON under these UPC codes or clicking this link: https://tinyurl.com/yc2y543u UPC codes B0B1BTNW4Q and B0B2R3D2TS.

Amazon.com: Rolls Choice Adhesive Pen (25, 1ml): Arts, Crafts & Sewing

ROLLS CHOICE has a pending trademark with the USPTO under the application number 972978083.
LITIGATION UPDATE
ADHC has filed suit in The Eight Judicial Circuit Court, Clark County, Nevada case Number A-21-843-670, seeking the cancellation of 330,000,000 (330 MM) shares of common stock. On January 6, 2023 the court granted the motion for default. Its is anticipated the court will be issuing the formal order soon on a scheduled hearing date on April 17th, 2023.
Granting the default judgment is the final legal step before all litigation is resolved.
Currently, ADHC capitalization structure is as follows:
Shares Outstanding: 1.1 billion
Shares Restricted: 600 million
Shares in the Float: 504 million

Investor Contact:
Ernest Remo
Chairman/CEO
ernestremo@san.rr.com
Tel: 858-259-4534
TWITTER: @ADHCManagement. This Twitter page is the only official twitter page for ADHC.

Information contained herein includes forward-looking statements.

SAFE HARBOR
These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different performance or achievements expressed. You should not place undue reliance on these statements since they involve known and unknown risks. Any forward-looking statements reflect the current view with respect to future events and subject to uncertainties.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

NEW YORK, Feb. 9, 2023 /PRNewswire/ – Today, HONA CBD, a brand that values respect, humility, integrity, innovation, quality, and executional excellence, announced their partnership with MILLIONS.co, the leader in online sports watch parties, to help connect, educate, promote, and provide transparency around their CBD products. HONA CBD, who just launched in December 2022, has signed a 2-year, 7-figure marketing deal to sponsor hundreds of athletes in MMA, Football, Golf, Tennis, Baseball, and more.

In Today’s world of marketing, brands need to stay on top of digital trends and rely on content creation, influencer marketing, and digital promotions. However, for CBD marketing in a digital world, it is extremely challenging and limited. HONA CBD is taking an innovative approach by partnering with a platform like MILLIONS, as they can use influential athletes to create authentic user-generated content on their new products, which can then be used for marketing and advertising on future campaigns.  “We believe that HONA has an incredible product and we’re excited to help use the power of our platform, WatchParty and our athlete network to help them in marketing it to the world” says CMO & Co-Founder of MILLIONS, Brandon Austin. “And it’s not just about the content however, the MILLIONS platform allows HONA to operate an effective marketing campaign driving brand awareness, trust, affinity, and product sales!”

MILLIONS.co is a social commerce platform that allows athletes to build their own brand, and connects brand sponsors to these pro, collegiate, and alumni athletes of all sports to host exclusive experiences and livestreams with their fans. Through this partnership, HONA CBD can take advantage of lower funnel campaigns and a large digital awareness strategy, as well as live-selling on the streaming platform.

Chris Whited, VP Marketing at HONA CBD said, “Our partnership with MILLIONS provides a first-hand experience through watch parties by connecting athletes and their live audience  while watching major sports events. The connection allows the audience to personally engage, ask questions and truly see how these athletes they love and trust are effectively using CBD products today.”

HONA, as a brand that just launched, is getting the chance to take advantage of the most prestigious sports marketing event, the Super Bowl, for a fraction of what brands would normally have to pay. HONA already hosted their first watch party events with MILLIONS on January 21, 2023, for UFC 283 with professional MMA fighters Liz Carmouche, Bi “Killer Bee” Nguyen , and Vanessa “Lil Monster” Demopoulos. “This was a great opportunity for HONA CBD to showcase their products and interact with the MMA fan base. Already, we’ve been able to deliver great results for HONA with immediate sales through our live-selling features on the streams and pre and post-event promotions with the athletes”, says CEO & Co-founder of MILLIONS, Matt Whitteker.

The two brands are excited for what the future holds for the partnership. Nicole Hicks, VP Ecommerce of Operations at HONA CBD, said, “When MILLIONS shared with us during our first meeting a key element of their operating philosophy ‘To start…We dream big!’ we knew we were with the right partner. These are the types of partnerships HONA CBD is looking for. Together we are bringing together uniquely formulated CBD products with a unique fun experience to learn and engage with your favorite athletes. As MILLIONS continues the path to growing into the largest athlete-centric merchandise and video engagement platform in the world, we want to be a part of this experience.”

About HONA CBD:

HONA CBD offers simple solutions that are easy to use, easy to love, and uniquely formulated to enhance your health and wellness journey. Their journey began with an idea from a farmer and encompasses a team of experienced individuals that value respect, humility, integrity, innovation, quality, and executional excellence. Their culture and values as a company emphasize the desire and love they have in helping others. At HONA CBD, they are a family that invests in their products because they care about your journey for better health and wellness.

About MILLIONS.co:

MILLIONS.co (www.MILLIONS.co) is quickly becoming the world’s leading social commerce and video platform connecting the sports world. MILLIONS combines the power of social media and e-commerce on a single platform to empower athletes to connect on a deeper level with their fans while creating new, lucrative revenue channels. It is rapidly proving to be the leading sports streaming and WatchParty platform.

SOURCE MILLIONS

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Partnership with Atlas to focus on U.S. market with immediate sales and marketing of U.S. Government approved products and laboratory collaboration to secure further FDA approvals

VANCOUVER, BC / ACCESSWIRE / December 19, 2022 / EMPOWER CLINICS INC (CSE:EPW)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, a medical device company and a high complexity medical diagnostics laboratory – today announced that it signed a partnership agreement with Alp Medtech AG (“ALP’) – the authorized representative of Atlas Medical Gmbh (“Atlas”), a European medical device company specializing in the distribution and manufacturing of invitro diagnostic tests and medical devices.

Atlas was founded in 1996 as a manufacturer and supplier of quality Diagnostic Reagents and kits. Their products are sold in more than 80 countries worldwide. Their product range comprises a comprehensive list of quality diagnostic products in the fields of serology, hematology, microbiology, immunology, histopathology, and biochemistry. Atlas has leading experience in technologies used in manufacturing diagnostic products such as clinical chemistry, nano-beads serology, immunoassays including ELISA and lateral flow rapid tests. Atlas is headquartered in Berlin, Germany with offices in U.K. and Turkey as well as two purpose built modern facilities in both Jordan and Malaysia. Atlas products meet the highest standards known in the industry including, ISO13485 & CE mark and US Food and Drug Administration (FDA).

The Partnership Agreement includes:

• Distribution rights by Empower for Atlas products in USA, Canada, Mexico, Central America, Australia, New Zealand
• Sales and Marketing launch of current FDA approved Atlas products in USA
• Utilization of MediSure Laboratory to seek FDA approvals for Atlas products
• Ongoing clinical study services by Empower’s MediSure Laboratory for FDA approval of Atlas products
• Support by Empower for Atlas and its partners to set up future USA manufacturing
• Potential investment by Atlas and its partners to support Empower’s growth plan

“Our partnership with Atlas will help accelerate both of our immediate growth plans in the U.S. market”, stated Steven McAuley, Chairman and CEO of Empower Clinics “Together we can generate short term revenues as a number of Atlas products are already FDA approved and only require sales and marketing support from Empower and our subsidiaries. Our longer-term collaboration can also drive further growth in the U.S. as together we secure U.S. FDA approvals for more Atlas products by leveraging our diagnostics laboratory and medical team for clinical studies.”

“We are very excited to enter the U.S. market in partnership with Empower”, said Dr. Raed Shadfan, Phd., founder of Atlas. “Atlas products and services have already seen success in Europe, Asia, and Africa. Together with Empower we look forward to growing our global presence and entering the massive U.S. market. Many of our products are already FDA approved and we were simply waiting for a partner like Empower to help us successfully expand our global reach. The combination of our global manufacturing and distribution expertise with Empower’s U.S. talent and laboratory presence is a synergy that will benefit more Americans to access affordable and convenient medical diagnostic devices.”

“Finding the right partner for the U.S. market has been a long and challenging process for our company until we met Steven McAuley”, stated Driffa Mezreg Chief of Staff

Alp Medtech AG. “Empower brings to the table the full solution we were looking for, a state-of-the-art laboratory to facilitate our regulatory needs as well as Medisure, a well-established medical device brand and distributor. We are very excited to be able to enter the U.S. market with such a strong partnership.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company with multi-disciplinary clinics, an at-home medical testing device company and state-of-the-art medical diagnostics laboratories. With a growing presence in the U.S. and Canada. Empower is a leader in integrated healthcare and diagnostics solutions and is reshaping the model for patient-first wellness.

ABOUT ATLAS MEDICAL:

Atlas Medical was established in 1996 as a manufacturer and supplier of quality Diagnostic Reagents and Kits. Our products are sold in over 80 countries worldwide. Our product range comprises a comprehensive list of quality diagnostic products in the fields of serology, hematology, microbiology, immunology, histopathology, and biochemistry. The company is located at Blankenfelde-Mahlow, Berlin, Germany .In addition to the German site, the company has offices in U.K and Turkey as well as two purpose built modern facilities in both Jordan and Malaysia. We take quality assurance very seriously and strive to produce goods to the highest standards known in the industry, including, ISO13485 & CE mark and US FDA standards. Our R&D team constantly develops and innovates novel products that significantly contribute to the advancement of the Diagnostic Industry.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Media:
Steven McAuley CEO
[email protected]
+1 855-855-9058

Investors:
Tamara Mason
Business Development & Communications
[email protected]
+1 855-855-9058

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the likelihood or ability for the Company to secure new testing business, that empower will granted distribution rights for US, Canada, Mexico, Central America, Australia and New Zealand, that the Empower will provide clinical study services and that such studies will result in a successful FDA approval leading to the sales and distribution of those products in the United States, that Atlas and its partners will set up USA manufacturing operations and that Empower will play a role at all, that Atlas and its partners will provide any investment support to Empower in the future. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company may be unable to enter into definitive agreements, or close transactions with respect to, proposed future clinic openings; that due diligence with respect to anticipated clinic openings and acquisitions may not be satisfactory to the Company; risks related to delays in permitting or construction; risks related to supply chains and access to labour; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for new clinics; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE: Empower Clinics Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The national chain of psychedelic mental-healthcare clinics growing rapidly

LOS ANGELES, Aug. 08, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of two ketamine clinics in Georgia through an asset purchase of Invictus Clinics, LLC, which will be brought into the fast-growing national chain of psychedelic mental-health facilities.

The clinics are located in Atlanta and Woodstock, Ga., operated under the name of the Invictus Clinic. They offer ketamine-assisted therapy, hydration via IV infusion as well as NAD+. They join Irwin Naturals Emergence, a national chain of mental-health facilities providing cutting-edge care behind a truly household brand name that is recognized in 80 percent of U.S. homes.¹

Klee Irwin, CEO of Irwin Naturals, said, “The vision we laid out for Irwin Naturals Emergence is becoming a reality with each acquisition we announce and execute. We wanted to be a first mover in this new and revolutionary area of healthcare, and adding these two clinics is further proof that we are a first mover in this space.”

Wesley Karcher, MSN, CRNA, Co-Founder of Invictus, added, “This is a huge opportunity for us to build upon our goals of creating a business capable of providing these life-changing treatments to those in need and making people aware of the effectiveness of our programs. A central mission at Irwin Naturals Emergence is to expand access and even serve as a bridge, in those instances, where we wait for the insurance industry to catch up to the power of ketamine and other psychedelics in mental healthcare. With this partnership, we are aligning our goals and hope to expand our footprint quickly throughout the Southeast and beyond.”

Brandon Grinage, MD, Co-founder, and Medical Director at Invictus, added, “I am delighted at the opportunity for Wesley and myself to partner with Irwin Naturals. From the very first conversation, it was apparent that our values and visions are aligned. Furthermore, this deal makes apparent our ambitions to raise mental health awareness and bring treatment to millions of Americans in dire need. I am humbled to be joining an organization that is rapidly becoming the tip of the arrow in the ketamine and psychedelic space.  Irwin Naturals Emergence will no doubt be a leader of mental health in this country.”

Over the past several months, Irwin Naturals Emergence has vetted the more than 600 independent ketamine clinics currently operating in the United States, seeking to identify profitable clinics that practice the standard of customer care consistent with the Irwin Naturals brand. The company has then invited those clinics into the family so to speak by joining Irwin Naturals Emergence in the national rollup that is now underway.

The acquisition of the two Georgia clinics completes the sale agreement that was announced June 21. When the month of July began, Irwin Naturals Emergence had binding agreements or had completed the acquisitions of a total of 10 different ketamine clinics across five different states.

Building a national chain will offer some efficiencies and the cost-benefits that come from economies of scale. It can also help drive down operating costs, a savings that can be passed on to customers by providing sliding-scale discounts and even pro bono treatment for those in need.

The Irwin Naturals brand will be like a beacon in this new area of mental-health treatment, bringing a level of not just familiarity but loyalty. Irwin Naturals has been in business since 1994, providing best-in-class nutraceuticals and earning the customer trust and popular recognition that have made it a household name. Irwin Naturals products are stocked on the shelves of more than 100,000 storefronts in North America.

Klee Irwin, Irwin Naturals CEO, “We’ve safely cared for your health needs for 28 years and that provides a level of assurance to those for whom this may feel new or maybe even controversial. We can sort of hold the hands of those looking into these new life-changing treatments. It’s safe. It’s effective. We send a message simply by being in the space.”

Transaction terms

As consideration for the acquisition, Irwin Naturals will provide sellers cash payments, as well as at least 333,333 Subordinate Voting Shares to be issued no later than January 10, 2023. Furthermore, the transaction includes an additional contingent consideration based on future milestones related to operational and profitability targets, to be satisfied in shares.

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class herbal supplement formulator since 1994. It is now leveraging its brand to enter into both the cannabis and psychedelic industries. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years². Irwin’s growing portfolio of products is available in more than 100,000 retail doors across North America, where nearly 100 million people know the Irwin Naturals brand.³ In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products across the United States. The Company is now leveraging its famous halo of brand trust with an objective to become one of the first household name brands to offer THC-based products and psychedelic mental health treatment. Irwin Naturals became a publicly traded company on the Canadian Securities Exchange (CSE) in August 2021. The Company’s shares began to be traded on the OTCQB Venture Market in November 2021. More information on the Company’s stock can be found via Bloomberg as well as the Wall Street Journal.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to [email protected].

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T:310-306-3636
[email protected]

IR Information

For investor-related information, please visit ir.irwinnaturals.com/, call (800) 883-4851, or email [email protected].

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
[email protected]

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, “objective,” or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. Forward-looking statements in this news release include statements related to information concerning the ability of the Company to perform the terms of the transaction referenced herein; the receipt of all necessary approvals, including regulatory approvals; expectations for other economic, market, business and competitive factors; and the Company actually entering into and doing business in the U.S. cannabis and psychedelics markets. The entrance by the Company into these new business segments are in their preliminary stages and may be subject to approval from the board of directors of the Company as well as any regulatory approval, including that of the Canadian Securities Exchange. These statements are based on numerous assumptions that are believed by management to be reasonable in the circumstances, and are subject to a number of risks and uncertainties, including without limitation: board and regulatory approval, including the approval of the Canadian Securities Exchange; Irwin being able to acquire and/or enter into business relationships to enter into these new markets; the Company obtaining the required licenses; and changes to regulations and laws regarding cannabis or psychedelics. Further information on the regulatory environment and risks will be contained in future disclosures. Forward-looking statements are subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from that which are expressed or implied by such forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

__________________________
¹ Based on a formal Company survey with a sample size of 500 randomly selected adults.
² Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.
³ Consumer brand recognition information is based on a formal Company survey with a sample size of 500 randomly selected adults.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Company continues national growth trajectory for Emergence clinics focusing on total wellness including the therapeutic use of ketamine

LOS ANGELES, June 17, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has entered into a binding agreement to acquire the assets of Hobie Fuerstman D O PLC, doing business as Preventive Medicine (“Preventive”), a clinic operation based in Colchester, Vermont.

Klee Irwin, CEO of Irwin Naturals, said, “Our roll-up is gathering momentum. This is the eighth ketamine clinic we are adding to our growing portfolio, which now covers four states, made up of acquired clinics and clinics under definitive agreements. Our mission is to make this amazingly effective treatment available and accessible throughout the country and beyond, and we are planning to acquire and build hundreds of clinics in the months and years to come. As we focus on acquiring profitable operations, we continue to add to our bottom line through these highly accretive transactions.”

Hobie Fuerstman, owner and director of Preventive, added, “We’re excited that Irwin Naturals has selected us to be the first Emergence partner in Vermont. There’s a lot of good that can come from merging with a nationally recognized and well-respected brand. Our mission has always and will always be, to provide the highest quality holistic care. This collaboration will allow us to amplify the reach of our integrative healthcare clinic, which means we can help more people without compromising our values.”

The Agreement is subject to certain customary closing conditions and regulatory approvals. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. Further detail will be provided upon closing.

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class nutraceutical company since 1994. It is now leveraging its brand into both the cannabis and psychedelic sectors. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years¹. The growing portfolio of products is available in more than 100,000 retail doors across North America, where 80% of households know the Irwin Naturals brand². In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become, perhaps, the first household name brand to offer THC-based products. Its rapidly growing national chain of psychedelic mental health clinics is called Irwin Naturals Emergence.

Klee Irwin
Chief Executive Officer
T: 310-306-3636
[email protected]

IR Information

For investor-related information, please visit ir.irwinnaturals.com/, call (800) 883-4851, or email [email protected].

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
[email protected]

Regulatory Overview

The following is a brief summary of regulatory matters concerning ketamine in the United States (“US”). Under the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), ketamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations, and psilocybin is currently a Schedule I drug.

Most US States have enacted Controlled Substances Acts (“State CSAs”) which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for much state and local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education.

In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency (“DEA“) to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a “DEA License“). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product’s labelling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the “FDA“). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment.

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry.

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.   Forward-looking statements in this news release include statements related to, information concerning the ability of the Company to complete the transaction referred to herein, the satisfaction of conditions to closing, the receipt of all necessary approvals including regulatory approvals, expectations for other economic, market, business and competitive factors. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

¹ Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.
² Based on a formal Company survey with a sample size of 500 randomly selected adults.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TORONTO, June 3, 2022 /CNW/ – TripSitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter” or the “Company”), today announced the official launch of the TripSitter App, a simple and free App that makes it easy for users to access TripSitter Clinics’ services.

CEO of TripSitter Clinic, Dr. Huber stated: “we are delighted to announce our new App launch which will enable users with a convenient platform for patients to connect to a doctor, and then be guided along their psychedelic healing journey with specially trained Tripsitters.

The App is available to users through Apple’s App Store and Google’s Play Store.  App features a compatibility assessment so patients will be matched with Tripsitters that share common interests and personalities.  The App features secure telehealth and unlimited messaging between patients and their Tripsitter and also enables scheduling, medication tracking, and billing

TripSitter Clinic is currently operating in Alabama, Arizona, California , Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Michigan, Minnesota, Mississippi, Montana, Nebraska, New Hampshire, New York, North Dakota, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming with continued expansion across the United States over the next 6 months.

ABOUT TRIPSITTER CLINIC LTD.

TripSitter Clinic LTD., through its wholly-owned subsidiary TripSitter Clinic Corp, is at the forefront of two emerging sectors: telehealth and psychedelic medicine. The Company’s consultative virtual clinic, TripSitter.Clinic, is an internationally-recognized SaaS platform that provides care, monitoring, and coaching while connecting patients with licensed physicians in the United States who can evaluate for a prescribed psychedelic treatment program of therapeutic low-dose ketamine medication. TripSitter is not a primary care physician (PCP). TripSitter.Clinic requires prospective patients to provide a diagnosis from their PCP along with other health information to their chosen TripSitter physician during the initial intake process. When a patient is approved for treatment by their physician, TripSitter.Clinic connects the patient with experts who also use the platform to consult and coordinate with the patient and their physician. Learn more at https://www.tripsitter.clinic/

ON BEHALF OF THE BOARD of DIRECTORS

Dr. John Huber, CEO
[email protected]

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

Disclaimer for Forward-Looking Information

This news release includes certain forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Forward-looking information in this news release includes statements concerning the Company’s general business plans, the tele-health industry and the Company’s market position within it, and statements concerning the listing of the Company’s common shares on the CSE. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the risk factors in the Company’s final long-form prospectus dated November 22, 2021, and the schedules attached thereto, that are available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tripsitterclinic-launches-new-app-for-at-home-ketamine-therapy-301560806.html

SOURCE TripSitter Clinic Ltd.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The psychedelics  sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar before moving on to the next opportunity, which makes it important for investors to know who’s at the helm.

Let’s take a look at what sets Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF)

management team apart and why its board members represent a strong vote of confidence in the team and business over the long-term.

Experienced Management

Delic was founded by veterans from the cannabis industry—another highly-regulated industry that went from zero to billions of dollars in just a handful of years.

Co-Founders Matt and Jackee Stang were executives at High Times, a leading counterculture publication that became the voice for the cannabis industry. In fact, the monthly magazine had a circulation of over 500,000 copies an issue, rivaling Rolling Stone, and its website attracted 500,000 to five million users each month by 2014 as cannabis took off.

Matt Stang was a previous owner and operator of High Times, was instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with all corners of the cannabis community for two decades, he helped found Delic two years ago as one of the first psychedelic corporations. His expertise in marketing, branding, business development and product viability and will prove invaluable as he shapes the company’s vision and path.

Most recently, John Coleman, Ph.D., former President of Anandia Labs, a cannabis biotech company focused on genetics and analytics, was hired as VP of Business Development. With a foot in both corporate and scientific worlds, Dr. Coleman is well-equipped to head up the company’s business development efforts as it looks to enter new vertical markets.

The company also recently hired Zak Garcia, former CMO of Bulletproof Inc., maker of the well-known Bulletproof® Coffee brand, as its Chief Marketing Officer. Mr. Garcia is a highly sought-after marketing and leadership strategist that helped grow Bulletproof® Coffee to over $250 million in revenue—experience that will help bring Delic to the next level of growth.

Click here to receive an investor presentation and corporate updates

Renowned Billion-Dollar Backers

Delic’s management team is supported by an impressive Board of Directors that reads like a who’s who of success stories in cannabis and other industries.

Paul Rosen was a co-founder of PharmaCan Capital Corp. and served as its first President and CEO.

Kraig Fox was a Senior Managing Director at Guggenheim Partners and later served as President and CEO of High Times. The involvement of these industry icons alone represents a big vote of confidence in the management team.

Mr. Rosen and Mr. Fox are joined by entrepreneur and venture capitalist Martin Tobias, finance veteran Sashko Despotovski and Dr. Markus Roggen, Founder and CEO of Complex Biotech Discovery Ventures. On the board of advisors, investors will find best-selling author Shep Gordon, Apollo Neuroscience Founder Dave Rabin and other leading voices.

The company’s well-known and respected board members provide a vote of confidence in the management team, valuable connections to grow its businesses and expertise that can be called upon to help make strategic decisions. With a wide range of expertise and disciplines, these team members could be invaluable in building long-term shareholder value.

Click here to receive an investor presentation and corporate updates

Looking Ahead

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is well-equipped to grow with its veteran executive team and its star-studded board of directors and advisors. With the right team in place, the company has been actively making acquisitions to become a strategic and diversified player in the nascent psychedelics industry today and well into the future. 

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.